Cardiac Monitors in Minnesota

Anteris Technologies is a cardiac medical device company focused on transcatheter aortic valve replacement (TAVR) solutions. The company develops and commercializes the DurAVR® Transcatheter Heart Valve (THV), a single-piece, native-shaped biomimetic device designed to mimic the performance of a healthy aortic valve. DurAVR® is engineered to address clinical gaps in aortic valve disease treatment, particularly for patients with small aortic annuli, where it demonstrates superior hemodynamic performance compared to competing TAVR platforms. Key clinical advantages include favorable effective orifice area (EOA), low mean pressure gradients, and notably high freedom from prosthesis-patient mismatch (PPM)—a recognized predictor of valve failure and long-term patient mortality. The company conducts clinical trials including the PARADIGM trial, the first all-comers, head-to-head TAVI comparison designed to evaluate post-procedure blood flow patterns using cardiac MRI. Anteris has FDA IDE approval and is enrolled across 80 centers in the US, Canada, and Europe. The company is publicly traded, with operations in Australia (Brisbane headquarters for annual meetings) and the US, as evidenced by SEC and ASX filings. Manufacturing and clinical development capabilities support valve design, bench testing, hemodynamic analysis, and multi-center clinical evaluation.

Nuwellis, Inc. is a commercial-stage medical device manufacturer specializing in ultrafiltration therapy systems for fluid management in cardiorenal patients. Founded in 1999 and headquartered in Eden Prairie, Minnesota, the company develops and markets the Aquadex FlexFlow System and Aquadex SmartFlow System—precision ultrafiltration devices designed to remove excess fluid in patients with heart failure, acute kidney injury, chronic kidney disease, and cardiorenal syndrome when diuretics prove inadequate. The systems deliver predictable, isotonic fluid removal while protecting organ function and reducing hospitalizations and readmissions. Nuwellis supports critical care, pediatric, nephrology, cardiology, and outpatient settings with comprehensive clinical evidence from 65+ peer-reviewed studies spanning 20+ years. The company provides integrated cardiorenal management solutions, clinical training, reimbursement support, and dedicated customer service to healthcare providers globally, addressing both acute perioperative fluid management and chronic disease management.

Osypka Medical, headquartered in Berlin, Germany, is a cardiovascular device manufacturer founded in 1986. The company specializes in non-invasive hemodynamic monitoring and temporary cardiac pacing systems. Its core technology platform, Electrical Cardiometry™ (EC™), provides continuous, non-invasive assessment of cardiovascular hemodynamics for critical care, perioperative, and emergency settings. The EC™ product portfolio includes the ICON® and ICONCORE® monitoring systems with disposable EC™ sensors. The company also manufactures temporary cardiac pacemakers under the PACE® brand, including Models 101, 203, and 300, for external pacing therapy and intrinsic rhythm assessment. Complementary product lines include temporary pacing leads (EndoStim®), myocardial electrodes (MyoStim®), and connecting cables (StimConnect®). Osypka offers the CORASIM® heart simulator for clinical training and research. The company maintains a robust educational platform through Osypka Meducate®, providing clinical training in electrical cardiometry and temporary pacing. Products are supported by published clinical evidence, including application in COVID-19 patient management. The company operates a distributor network and provides comprehensive technical support and service. All devices are designed for use in acute care, ICU, operating room, and emergency department environments.

VivaQuant, Inc. (operating as Rhythm Express) is a remote cardiac monitoring company specializing in portable, wireless ECG/cardiac monitoring solutions for healthcare providers and patients. Their flagship product, the RX-1 mini, is an all-in-one, water-resistant (IP64) wearable device designed for continuous cardiac monitoring with uninterrupted data collection. The device combines multiple monitoring capabilities in a single compact form factor, enabling seamless patient compliance through lifestyle-compatible design, including shower capability. The company serves over 600 clinics and healthcare facilities nationwide, with a track record of monitoring 600,000+ patients. Rhythm Express delivers comprehensive cardiac data analysis, including enhanced P-wave detection, with actionable reporting available typically within 24–48 hours and event notifications within 20 minutes. The platform integrates dual connectivity (cellular and Wi-Fi) for real-time data transmission and includes a cloud-based portal for clinician workflow integration. Business model offerings include subscription-based pricing, fee-for-service, and split-bill arrangements, designed to minimize upfront costs and provide predictable monthly pricing without hidden fees. The company provides 24/7 technical support and continuous device/software updates. Based in Arden Hills, Minnesota, VivaQuant delivers cardiac monitoring solutions positioned at the intersection of remote patient monitoring, home healthcare, and cardiology practice efficiency. Products are designed for both in-home patient monitoring and clinical practice settings.

R&D Batteries, Inc. is a multi-million dollar battery assembler and distributor specializing in replacement batteries for medical equipment. The company maintains factory-direct relationships with premier cell manufacturers including Sanyo, Panasonic, Powersonic, Yuasa, FDK, Enersys, Sonnenschein, Varta, Saft, Energizer, and Renata. Their medical battery portfolio includes solutions for infusion pumps (Baxter Sigma Spectrum, Alaris Medley, ICU Medical Plum A+), defibrillators and AED systems (Physio-Control Lifepak, Zoll R Series, Cardiac Science PowerHeart), patient monitoring devices (GE Marquette, Philips AVALON FM20, Welch Allyn), and emergency medical equipment. Beyond medical batteries, R&D Batteries supplies replacement batteries for UPS backup systems, emergency lighting, communication devices, and other industrial applications. The company emphasizes engineering, testing, manufacturing, and distribution capabilities with ISO 13485 certification (MDSAP compliant), in-house production quality control, and direct supply-chain partnerships enabling competitive pricing and rapid fulfillment.

Resolution Medical is a medical device development and manufacturing partner specializing in complex catheter delivery systems, active implantable devices, and component manufacturing. The company serves structural heart, cardiology, vascular, heart failure (VAD), neuromodulation, electrophysiology, and additional specialty markets including ENT, neurology, urology, oncology, endoscopy, and robotics. Core capabilities span the full product lifecycle: concept and design development, BioSimulation and testing with cardiovascular visualization in pressurized heart models, New Product Introduction (NPI) with design-for-manufacturing optimization, and end-to-end manufacturing from prototyping through commercial production. Resolution Medical operates specialized clean rooms, sterile packaging, labeling, and distribution infrastructure. In structural heart, the company develops implants and catheter delivery systems for mitral, tricuspid, aortic, and pulmonary valve interventions, as well as shunts, stents, closure devices, and embolic protection. Cardiology and vascular expertise includes complex delivery platforms, imaging and sensing catheter systems for peripheral, neurovascular, and cardiovascular applications, DVT/PE management, drug delivery, and flow management. Heart failure capabilities encompass VAD pump development, drivelines, and deployment systems. Neuromodulation focus includes Class III active implantables: implantable pulse generators (IPGs), leads, headers, adapters, and subassemblies for spinal cord stimulation, deep brain stimulation, vagus nerve stimulation, and peripheral nerve modulation. Electrophysiology specialization covers diagnostic mapping and energy delivery catheters with modalities including pulsed field ablation (PFA), RF energy, cryotherapy, and vapor therapy. The company maintains a quality management system per ISO 13485:2016 and operates under FDA guidelines. Resolution Medical was recently acquired by Resonetics (2025) and operates with 100+ engineers backed by 1,000+ combined years of experience.

CVRx is a medical technology company specializing in neuromodulation therapies for heart failure management. The company's flagship product, Barostim, is an implantable device that delivers gentle electrical pulses to baroreceptors on the carotid artery to modulate neural signals and reduce heart failure symptoms. Clinical evidence demonstrates that Barostim improves exercise capacity (patients walk approximately 60 yards farther in 6-minute testing), quality of life (3x greater improvement vs. medication alone), and symptom relief, with 94% of patients experiencing significant improvement in quality of life, exercise capacity, or heart failure symptoms. The minimally invasive implant procedure typically takes about one hour with same-day discharge and a 97% freedom-from-complications rate. CVRx provides comprehensive support services to healthcare providers, including patient access assistance and reimbursement support to ensure eligible patients can access baroreflex activation therapy.

Solo Pace Inc manufactures temporary pacing technology and systems engineered specifically for transcatheter heart valve (THV) procedures. The company specializes in precision pacing solutions that provide confident control during valve deployment while reducing patient risk. Product lines include the SoloPace CONTROL™ System, an innovative pacing platform designed to reduce pacing risk and improve procedural efficiency during THV interventions, and the SoloPace FUSION™ System, a fully integrated sterile kit that combines temporary intracardiac pacing with streamlined THV device delivery. These solutions address a critical clinical need in structural heart interventions where reliable, precise temporary pacing is essential during transcatheter aortic valve replacement (TAVR) and other valve procedures. The company serves interventional cardiologists, structural heart specialists, and cardiac catheterization laboratories. Solo Pace's products are designed for hospital-based cardiac catheterization and hybrid operating room environments. Specific regulatory certifications and manufacturing details are not provided on the available website content.